Reações de hipersensibilidade à vacina contra o vírus Sars-Cov-2
Hypersensitivity reactions to the Sars-Cov-2 virus vaccine
DOI:
https://doi.org/10.34119/bjhrv5n6-119Keywords:
COVID-19, vacinas, reações, hipersensibilidadeAbstract
A COVID-19, doença infectocontagiosa causada pelo vírus Sars-Cov-2, causou uma pandemia que impactou a saúde e a economia globalmente, desde então, a vacinação tem sido a estratégia mais confiável para controlar a disseminação dessa enfermidade. Conforme as primeiras doses foram aplicadas, diversos casos de reações adversas foram reportados, incluindo casos de hipersensibilidade. A hipersensibilidade ocorre devido a reações excessivas do sistema imunológico que podem causar danos ao paciente. Devido a ocorrência desses eventos, é necessário entender o espectro das reações causadas pelas vacinas contra a COVID-19, para que seja possível formular uma opinião concreta sobre o assunto. Nesse sentido, este trabalho tem como objetivo revisar pesquisas prévias que tratam acerca da incidência das reações de hipersensibilidade às vacinas contra o vírus Sars-Cov-2 e discutir suas possíveis causas. Com esse intuito, foram analisados 11 artigos acerca do tema, e após observados os resultados, concluiu-se que a grande maioria das reações aconteceu de forma autolimitada, e não ofereceram grande risco de vida quando comparadas com os desfechos causados pela própria doença, logo cada caso deve ser avaliado individualmente. Além disso, ainda não é possível definir com certeza o componente da vacina responsável pelas reações.
References
ALHUMAID S, et al. Anaphylactic and nonanaphylactic reactions to SARS-CoV-2 vaccines: a systematic review and meta-analysis. Allergy Asthma Clin Immunol. 2021 Oct 16;17(1):109. doi: 10.1186/s13223-021-00613-7. PMID: 34656181; PMCID: PMC8520206.
Bae S, Lee YW, Lim SY, Lee J-H, Lim JS, Lee S, et al. Adverse reactions following the first dose of ChAdOx1 nCoV-19 vaccine and BNT162b2 vaccine for healthcare workers in South Korea. J Korean Med Sci. 2021;36(17):e115. doi: 10.3346/jkms.2021.36.e115
Banerji A., Wickner P.G., Saff R., Stone C.A., Jr., Robinson L.B., Long A.A., Wolfson A.R., Williams P., Khan D.A., Phillips E., et al. mRNA vaccines to prevent COVID-19 disease and reported allergic reactions: Current evidence and suggested approach. J. Allergy Clin. Immunol. Pract. 2021;9:1423–1437. doi: 10.1016/j.jaip.2020.12.047.
Beatty AL, Peyser ND, Butcher XE, et al. Analysis of COVID-19 Vaccine Type and Adverse Effects Following Vaccination. JAMA Netw Open. 2021;4(12):e2140364. doi:10.1001/jamanetworkopen.2021.40364
Centers for Disease Control and Prevention (CDC) COVID-19 Response Team Allergic Reactions including Anaphylaxis after Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine—United States, December 14–23. Acesso em 10 de outubro de 2022; https://www.cdc.gov/mmwr/volumes/70/wr/mm7002e1.htm
Centers for Disease Control and Prevention (CDC) COVID-19 Response Team Selected Adverse Events Reported after COVID-19 Vaccination. Acesso em 10 de outubro de 2022; https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/adverse-events.html
Falsey A.R., Sobieszczyk M.E., Hirsch I., Sproule S., Robb M.L., Corey L., Neuzil K.M., Hahn W., Villafana T., Gonzalez-Lopez A., et al. AstraZeneca AZD1222 clinical study group. Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine. N. Engl. J. Med. 2021;385:2348–2360. doi: 10.1056/NEJMoa2105290
García‐Irigoyen A, Acatitla‐Acevedo GA, Barrera‐Godínez A, Méndez‐Flores S, Domínguez‐Cherit J. Follow‐up of dermatological manifestations in non‐critical hospitalized patients with COVID‐19 pneumonia and their prognostic correlation with disease severity. J Eur Acad Dermatol Venereol. 2021;35(7): 10.1111/jdv.17236
Jimenez-Rodriguez T, Garcia-Neuer M, Alenazy LA, Castells M. Anaphylaxis in the 21st century: phenotypes, endotypes, and biomarkers. J Asthma Allergy. 2018;20(11):121–142. doi: 10.2147/JAA.S159411.
Klein N.P., Lewis N., Goddard K., Fireman B., Zerbo O., Hanson K.E., Donahue J.G., Kharbanda E.O., DeStefano F., Weintraub E.S., et al. Surveillance for adverse events after COVID-19 mRNA vaccination. JAMA. 2021;326:1390–1399. doi: 10.1001/jama.2021.15072.
Luxi N, Giovanazzi A, Arcolaci A, Bonadonna P, Crivellaro MA, Cutroneo PM, Ferrajolo C, Furci F, Guidolin L, Moretti U, Olivieri E, Petrelli G, Zanoni G, Senna G, Trifirò G. Allergic Reactions to COVID-19 Vaccines: Risk Factors, Frequency, Mechanisms and Management. BioDrugs. 2022 Jul;36(4):443-458. doi: 10.1007/s40259-022-00536-8. Epub 2022 Jun 13. PMID: 35696066; PMCID: PMC9190452.
McMahon DE, Amerson E, Rosenbach M, et al. Cutaneous reactions reported after Moderna and Pfizer COVID‐19 vaccination: A registry‐based study of 414 cases. J Am Acad Dermatol. 2021;85(1):46‐55.
McNeil M.M., Weintraub E.S., Duffy J., Sukumaran L., Jacobsen S.J., Klein N.P., Hambidge S.J., Lee G.M., Bednarczyk R.A., DeStefano F., et al. Risk of anaphylaxis after vaccination in children and adults. J. Allergy Clin. Immunol. 2016;137:868–878. doi: 10.1016/j.jaci.2015.07.048
Polack F.P., Thomas S.J., Kitchin N., Absalon J., Gurtman A., Lockhart S. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383:2603–2615.
Risma K.A., Edwards K.M., Hummell D.S., Little F.F., Norton A.E., Stallings A., Wood R.A., Milner J.D. Potential mechanisms of anaphylaxis to COVID-19 mRNA vaccines. J. Allergy Clin. Immunol. 2021;147:2075–2082.e2. doi: 10.1016/j.jaci.2021.04.002
Sa S, Lee CW, Shim SR, Yoo H, Choi J, Kim JH, et al. The Safety of mRNA-1273, BNT162b2 and JNJ-78436735 COVID-19 vaccines: safety monitoring for adverse events using real-world data. Vaccines (Basel). 2022;10(2):320. doi: 10.3390/vaccines10020320
Sellaturay P., Gurugama P., Harper V., Dymond T., Ewan P., Nasser S. The polysorbate containing AstraZeneca COVID-19 vaccine is tolerated by polyethylene glycol (PEG) allergic patients. Clin. Exp. Allergy. 2022;52:12–17. doi: 10.1111/cea.14064.
Selvaraj G., Kaliamurthi S., Peslherbe G.H., Wei D.Q. Are the allergic reactions of COVID-19 vaccines caused by mRNA constructs or nanocarriers? Immunological insights. Interdiscip. Sci. 2021;13:344–347. doi: 10.1007/s12539-021-00438-3.
Shavit R, Maoz-Segal R, Iancovici-Kidon M, Offengenden I, Haj Yahia S, Machnes Maayan D, et al. Prevalence of allergic reactions after Pfizer-BioNTech COVID-19 vaccination among adults with high allergy risk. JAMA Netw Open. 2021;4(8):e2122255. doi: 10.1001/jamanetworkopen.2021.22255.
Shimabukuro TT, Cole M, Su JR. Reports of anaphylaxis after receipt of mRNA COVID-19 vaccines in the US—December 14, 2020-January 18, 2021. JAMA. 2021;325(11):1101–1102. doi: 10.1001/jama.2021.1967.
Tan SW, Tam YC, Pang SM. Cutaneous reactions to COVID-19 vaccines: A review. JAAD Int. 2022 Jun;7:178-186. doi: 10.1016/j.jdin.2022.01.011. Epub 2022 Feb 17. PMID: 35194586; PMCID: PMC8849859.
Temiz SA, Abdelmaksoud A, Wollina U, Kutlu O, Dursun R, Patil A, Lotti T, Goldust M, Vestita M. Cutaneous and Allergic reactions due to COVID-19 vaccinations: A review. J Cosmet Dermatol. 2022 Jan;21(1):4-12. doi: 10.1111/jocd.14613. Epub 2021 Nov 17. PMID: 34791757; PMCID: PMC8661794.
Warren CM, Snow TT, Lee AS, Shah MM, Heider A, Blomkalns A, et al. Assessment of allergic and anaphylactic reactions to mRNA COVID-19 vaccines with confirmatory testing in a US Regional Health System. JAMA Netw Open. 2021;4(9):e2125524. doi: 10.1001/jamanetworkopen.2021.25524.
Wood R.A. Allergic reactions to vaccines. Pediatr Allergy Immunol. 2013;24:521–526.
